Evaluation of a Guided Machine Learning Approach for Pharmacokinetic Modeling by Agrawal, Anurag (Author) et al.
Evaluation of a Guided Machine Learning Approach for Pharmacokinetic Modeling
by
Anurag Agrawal
A Thesis Presented in Partial Fulfillment
of the Requirements for the Degree
Master in Science
Approved July 2017 by the
Graduate Supervisory Committee:
Sandeep Gupta, Chair
Ayan Banerjee
Yogish Kudva
ARIZONA STATE UNIVERSITY
August 2017
ABSTRACT
A medical control system, real-time controller, uses a predictive model of human
physiology for estimation and controlling of drug concentration in the human body.
Artificial Pancreas (AP) is an example of control system which regulates blood glu-
cose in T1D patients. The predictive model in the control system such as Bergman
Minimal Model (BMM) is based on physiological modeling technique which separates
body into the number of anatomical compartments and each compartment’s effect
on body system is determined by their physiological parameters. These models are
less accurate due to unaccounted physiological factors effecting target values. Esti-
mation of large number of physiological parameters through optimization algorithm
is computationally expensive and stuck in local minima. This work evaluates a ma-
chine learning(ML) framework which has a ML model guided through physiological
models. A support vector regression model guided through modified BMM is im-
plemented for estimation of blood glucose levels. Physical activity and Endogenous
glucose production are key factors that contribute in the increased hypoglycemia
events thus, this work modifies Bergman Minimal Model Bergman et al. (1981) for
more accurate estimation of blood glucose levels. Results show that the SVR out-
performed BMM by 0.164 average RMSE for 7 different patients in the free-living
scenario. This computationally inexpensive data driven model can potentially learn
parameters more accurately with time. In conclusion, advised prediction model is
promising in modeling the physiology elements in living systems.
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Chapter 1
INTRODUCTION
Control Systems, real time systems, have MPC - Model Predictive Controller -
which regulates or controls substance’s concentration in human body. MPC consists
of a predictive model of human physiology for estimation. Physiological modeling,
a mathematical technique, which separates human body into different compartments
and compartment’s effectiveness on blood or fluid is determined by physiological
parameters. These models are widely used to estimate optimal drug scheduling and
dosage.
Physiological models consist of complex non-linear differential equations for quan-
tification of substance in each compartment and its parameters represent the biolog-
ical effect on blood flows. These models are also used for statistical inference in risk
assessment and drug scheduling, however these models have certain set of limitations.
a) Physiological Parameters: The human population is biologically heterogeneous
which means there are variations in physiology, biochemistry and molecular biology
among individuals. This heterogeneity results in differences amid individual’s biolog-
ically effective tissue dose associated with a given administered dose which in-turn
makes physiological parameters individuals specific. These physiological parameters
are not just individual dependent, in fact, they are also diurnal in nature ( Lee et al.
(1992)) and are quite few in number. Thus every-time estimation of parameters for
every individual is required. This estimation is generally done by an optimization
algorithm such as convex optimization. b) Factors or Variables: Human body is
complex in nature where every thing is related to each other in some form, It is
quite difficult to consider every factor’s effect while estimating the drug. Absence of
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all the affecting factors constrain the usage of these models in free living scenarios
for example, Bergman minimal model doesn’t account physical activity, endogenous
glucose production and other factors due to which it works well only during fasting
condition. c) To build a online system it should consist of a model which can be used
in a plug-n-play manner. This means one should be able to add, remove or update
the model without reconfiguring the whole system. Due to these limitations, there
are three problems in using physiological model a) Due to its high computation, it
is not easily affordable b) When there is absence of effecting features in the physio-
logical model, predictions are less accurate for example, as shown in the evaluation,
when Bergman Minimal Model ( Bergman et al. (1981)) was factored in with physical
activity, accuracy was increased significantly C) Due to the constrained usability, it
can’t be practically used in free living scenario.
In this work, our approach is to developed a guided machine learning model for
pharmacokinetic modeling. A machine learning(ML) algorithm is applied on top of a
generic physiological model for prediction of a physiological feature. This means ML
takes informative features generated through physiological model along-with other
important features for prediction. This guiding is necessary because it provides base
values for prediction, as the physiological datasets are generally skewed. This frame-
work eliminates the need for estimation of individualized parameters and machine
learning algorithms with informative features are quite less expensive when compared
against physiological models. With these advantages over physiological models, this
framework can be used in a plug-n-play manner.
We have evaluated our proposed approach by developing a guided support vector
regression model for prediction of blood glucose. In this model, a modified Bergman
Minimal Model(BMM) ( Bergman et al. (1981)) is used to generate informative data
for support vector regression machine learning algorithm. Since, according to Chimen
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et al. (2012), regular physical activity improves anomalies of the multi- metabolic
syndrome: increase in insulin sensitivities, diminution in the fatty mass, improvement
of the lipid profile, increase of the fibrinolysis and arterial pressure decrease and
incidence reduction of the non insulin dependent diabetes and endogenous glucose
production provides glucose when BG levels goes below certain levels. Thus, in this
work Bergman minimal model is modified to add physical activity and endogenous
glucose production effects on BG levels for more accurate estimation. As per our
experiment evaluation, proposed regression model outperforms BMM by average 0.24
RMSE values. There was a significant amount of improvement, improved by 0.2
RMSE, when regression model was guided with modified BMM.
This thesis is structured as follow. Section 2 talks about the background and state-
of-the-art SVR modeling and blood glucose management, Chapter 3 describes our
guided machine learning approach. Chapter 4 explains modified Bergman Minimal
Model . Chapter 5 lists the experiments performed and analysis drawn from the
experiments. Chapter 6 concludes with future work on this novel approach.
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Chapter 2
BACKGROUND
2.1 Support Vector Regression
Support Vector Machines(SVM), developed at AT&T Bell Laboratories by Vapnik
and co-workers [ Boser et al. (1992), Guyon et al. (1993), Cortes and Vapnik (1995),
Schiilkop et al. (1995), Scho¨lkopf et al. (1996), and Vapnik et al. (1997)], are learning
machine based on structural risk minimization inductive principles which aims in
obtaining good generalization through learning patterns. SVM has two categories,
Support Vector Classification and Support Vector Regression (developed in 1997 by
Vapnik, Steven Golowich, and Alex Smola).
In Support Vector Regression technique, the basic objective is to find a function
f(n) that has atmost  deviation from target yi in the given training data and in
parallel it should be as flat as possible. This means SVR algorithm doesn’t care about
the error until the loss is less than . Lets consider the dataset (x1, y1), ......(xl, yl) ⊂
X × R where X denotes the input feature space. In the linear case, the obtained
function is in the form of
f(x) =< W,X > +b W ∈ X, b ∈ R (2.1)
where < ., . > denotes the dot product in the obtained equation. As stated by Smola
and Scho¨lkopf (2004), this optimization can be considered as convex optimization.
Minimize
1
2
||W ||2 (2.2)
4
Subject to

yi − (w, xi)− b ≥ 
(w, xi) + b− yi, ≥ 
(2.3)
where yi are target labels, ||W || is the Euclidean norm of W , W is the normal
form of the decision plane.
Figure 2.1: The Margin Loss Setting for linear SVR . Source: Smola and Scho¨lkopf
(2004)
2.2 Bergman Minimal Model
A closed loop insulin delivery system also known as Artificial Pancreas (AP) auto-
mates blood-sugar management, exponentially reducing hypoglycemia events. Closed
loop insulin delivery system consists of a glucose monitoring device which calculates
BG levels every 5 minutes, an insulin pump which infuses insulin inside the body
and a controlled algorithm which would estimate the amount of insulin required to
be delivered. This section discusses a control algorithm which requires a mathe-
matical model, Bergman Minimal Model, that predicts BG levels by estimating the
pancreatic responsiveness and insulin sensitivity towards blood glucose. Further, this
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section also discusses a modification in the mathematical model to include the effect
of carbohydrate intake on BG levels while estimating it. At the end, this section
talks about different literatures which outline the effect of physical activity and the
importance of endogenous glucose production on BG levels.
2.3 Blood Glucose Regulation for T1DM
Figure 2.2: Blood Glucose Regulation when BG levels is high.
BG levels regulation highly depends on the amount of insulin secreted by pancre-
atic β cells and effectiveness of insulin on disposing carbohydrate intake. In order to
understand more about T1DM diabetes, figure 2.2 shows how BG levels is maintained
in normal non-diabetic person. As described in the figure, when BG levels go high,
pancreas β cells produce insulin which decreases BG levels to normal range whereas,
in case of T1DM diabetes, pancreatic β cells are not capable of producing insulin to
decrease BG levels. Richard Bergman and his fellow colleagues developed a model
to estimate right amount of insulin required by a body for maintaining BG levels in
normal range.
Bergman et al. (1981) developed a two compartment minimal model to quantify
both pancreatic responsiveness and insulin sensitivity to the entire organism. Pan-
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creatic responsiveness is the ability to dispose carbohydrates and insulin sensitivity is
the sensitivity of insulin on disposing off blood glucose. The author has interpreted
the dynamics of the plasma glucose and insulin through two mathematical equations.
One equation, the insulin kinetics model, yields parameters which depict the pancre-
atic responsiveness to glucose and second equation, glucose kinetics, yields the insulin
sensitivity to glucose.
Figure 2.3: Minimal model of Glucose Kinetics. Source : Bergman et al. (1981)
The Bergman et al. (1981) has followed a partition and minimal modeling ap-
proach. The glucose concentration regulation system is partitioned into two parts:
(a) the glucose dependent segment which determines the plasma insulin. (b) the in-
sulin dependent segment which determines the plasma glucose (glucose producing and
utilizing tissues). The two segments are used to estimate the parameter of insulin
sensitivity SI and parameters of pancreatic responsiveness to glucose respectively.
Figure 2.3 represents glucose kinetics which would calculate parameter of insulin
sensitivity. The coefficients of the minimal model are estimated by allowing model
to predict the observed fall in plasma-glucose when the measured plasma−insulin
is supplied. SI can be calculated as the ratio of two of the parameters of glucose
disappearance model. The ratio is proportional to the concentration of ”active”
7
insulin in a compartment remote from plasma, and the ability of that insulin to
enhance glucose disappearance.
Figure 2.4: Minimal model of Insulin Kinetics. Source : Bergman et al. (1981)
Figure 2.4 represents insulin kinetics which would quantify parameters of pan-
creatic responsiveness to glucose, φ1 and φ2. In this model, the author assumed that
the early peak in insulin secretion depicts the injection of insulin into plasma by the
pancreas in direct proportion to the rise in glucose. φ1 responsivity is the amount
of insulin that can be accounted by this assumed insulin injection per unit change in
BG levels whereas φ2 responsivity is proportionality factor between glucose and the
rate of arrival.
Later the above insulin-glucose dynamics model was modified for more accurate
estimation of input values, an additional meal sub-model is used to describe meal
dynamics by Hovorka et al. (2004); Gillis et al. (2007) .According to the Gillis et al.
(2007), as shown in figure 2.5, the meal sub- model is a two compartment based
model in which glucose appearance in first-compartment is the glucose calculated
from carbohydrate intake whereas, second compartment contains plasma appearance
glucose which would directly impact BG levels.
2.4 Endogenous Glucose Production and Physical Activity
Blood glucose regulation is not just all about insulin and meal intakes. There
are other physiological factors - endogenous glucose production (EGP) and physi-
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Figure 2.5: Two Compartment based Meal Sub Model
cal activity - as well which play an important role in maintaining blood glucose in
normal range. As described in figure 2.6, when BG levels decease from the nor-
mal range, pancreatic α cells detect this change and release glucose from glucagon
through glycogenolysis and gluconeogenesis process. It is well know that physical
activity, bodily movements, consumes energy and according to the Breton (2008) ,
BG levels decreases with consumption of energy.
According to Young (2005), Glucagon primarily acts on liver to initiate glycogenol-
ysis and gluconeogensis, resulting in a rapid increase in endogenous glucose produc-
tion. With prolonged stimulation, glucagon action at the liver results in a glucose
sparing activation of fatty acid oxidation and production of ketones. As said in
the Young (2005) paper, there are two kinds of stimulated glucagon secretion, hy-
poglycemia and nutrient. In any case, it is quite necessary to include the effect of
endogenous glucose production in blood glucose regulation for better accuracy.
As mentioned by Yardley et al. (2012), insulin sensitivity changes when a person
9
Figure 2.6: Endogenous Glucose Production Process
with T1DM diabetes exercises and these changes affect responsiveness of insulin on
glucose. Similarly, Colberg et al. (2015) states that many individuals experience a
decline in post-activity glucose levels during night-time. Currently insulin pumps are
available which take into account insulin basal bolus, glucose distribution, and meal
intake. However, these insulin pumps have sheltered the effects of physical activity
on blood glucose though, as stated in my litertaure, it is quite factor in blood glucose
management. Thus, we have modified Bergman Minimal Model to include effects of
physical activity and endogenous glucose production.
2.5 Optimization Algorithm: Least Square Function
Optimization algorithms are used for approximation of unknowns in given equa-
tions. Least square functions are widely used for optimization algorithms where best
curve fitting is done by minimizing residuals( a residual being: the difference between
an observed value and the fitted value obtained from given model). Least square fall
into two categories: linear and non linear least squares, depending on the linearity of
given equations and unknowns.
Consider a set of m data points, (x1, y1), (x2, y2), ..., (xm, ym), and a mathematical
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model y = f(x, P ), x depends on the n parameters, P = p1, p2, ...., pn with m > n.
The objective is to find P such that the curve fits best the given data by minimizing
the sum of squares
S =
m∑
1
r2i (2.4)
is minimized, where errors ri,
ri = yi − f(xi, P ) for i = 1, 2, 3.....m (2.5)
Minimum value of S can be obtained when the gradient is zero. Therefore, n
gradient equations:
∂S
∂pj
= 2
∑
i
ri
∂ri
∂pj
= 0 (j = 1, 2, ...., n) (2.6)
The derivatives ∂ri
∂pj
consists of independent variables and the parameters, hence
these equations don’t have a closed solution. Therefore, initial values of parameters
are given and these are updated iteratively.
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Chapter 3
RECENT WORK AND APPROACHES
With the availability of real-time monitoring sensors, there has been a boost in
the research of closed loop insulin delivery systems, also know as artificial pancreas.
Artificial pancreas is a system of body sensors which closely caricatures the blood glu-
cose regulation of a healthy pancreas. This system mainly consists of three devices,
continuous glucose monitoring sensor(CGM) for measuring BG levels in the subcu-
taneous tissue, a controlled algorithm to calculate the amount of insulin that has to
be delivered and a continuous SC insulin infusion (CSII) pump to deliver calculated
insulin. The controlled algorithm uses MPC - model predictive controllers approach
- which estimate the amount of insulin through a non linear complex differential
equation. According to the Cobelli et al. (2011), control algorithm needs further
development in the areas of model prediction, individualization, automated meal and
exercise control and real-time adaptation to patient physiology and behavior.
Dr Breton, in 2008, proposed a modified minimal model for glucose kinetics(MMGK)
( Breton (2008)) which accounted physical activity in closed loop insulin delivery sys-
tem. This model considers both increased glucose uptake due to increased energy
consumption and longer lasting changes in insulin action. Below are the modified
equations for estimation of glucose.
dG
dt
= −p1(G−Gb)− (1 + αZ)X.G− βY G+ D
Vg
(3.1)
dX
dt
= −p2 + p3(I − Ib) (3.2)
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dY
dt
=
−1
τHR ∗ Y +
1
τHR
(HR−HRb) (3.3)
dZ
dt
= −(f(Y ) + 1
τ
)Z + f(Y ) (3.4)
where, f(Y ) =
( Y
a.HRb
)n
1+( Y
a.HRb
)
n . In this model exercise intensity and duration were
accounted for through the use of heart rate. Physiological parameters were fit using
a combination on non-linear least-square fitting and Bayesian constraints. There are
two major things which this model did not considered, modeling of endogenous glucose
production and the change in insulin sensitivity due to the activities preformed in last
24-hours.
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Chapter 4
GUIDED MACHINE LEARNING MODELING APPROACH
4.1 System Layout
The proposed System, figure 4.1, consists of two models, Physiological model and
ML model. Physiological model, guide to ML model, generates informative features
through raw physiological data. ML generates a patient specific predictive model
through the input features which also includes informative feature obtained from
physiological model along-with other features.
Figure 4.1: Guided System Layout
Suppose, we have a physiological dataset with [x1, x2, ..., xn] features and the target
value [Y ], has to be estimated. As mentioned in Bischoff (1987), physiological model
is constructed from a set of differential equations and its respective physiological
parameters. Hence we can represent the model’s equation in the following way:
14
y0 × dy
dt
= p1 × dx1
dt
+ p2 × dx2
dt
...+ pn × dxn
dt
(4.1)
The Y
′
, informative feature obtained by solving the non linear differential equa-
tions, is passed on to the ML algorithm along-with other input features, [x
′
1, ..., x
′
n, Y
′
].
ML algorithm learns a model through these features and generates a predictive func-
tion, h(x). Considering h(x) as a linear function, we can represent it as below:
h(x) = θ1 + θ2 × x′1 + ...+ θn+1 × x
′
n + θn+2 × Y
′
(4.2)
Subjectto h(x)− Y <  (4.3)
These [θ1 + .. + θn+2] weights are maximized such that h(x) − Y is always less
than  - error threshold - for the given training dataset. If an input feature xi is
more correlated as compare to other feature then, its impact on the predicted values
will be more. Hence, more accurate estimated values from physiological model as a
informative feature will give more accurate result from ML model.
4.2 Guided Support Vector Regression Machine
This section talks about a guided machine learning model, Support Vector Re-
gression Model, developed based on the system framework described in the previous
section. This model, guided by a glucose regulation physiological model, predicts the
blood glucose levels of T1DM patients in living scenario.
This model has four input features - estimated blood glucose levels, insulin input,
intensity of physical activity and food intake. Estimated blood glucose levels are
the values generated through the physiological model used in this system. Insulin
input is the amount of insulin taken by the patients. It includes both intravenous
insulin (bolus) and subcutaneous insulin input (basal). Intensity of physical activity
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is the amount of activity done that particular time interval. It is calculated through
accelerometer values. Food intake accounts for the amount of carbohydrate comsumed
by a patient. All the input data is standardized to zero mean and unity standard
deviation. This preprocessing is done for two reasons, all the input features are
measured at different scale and this allow regression model to converge at a faster
rate.
This model predicts blood glucose levels in an iterative manner which means
it takes 576 data points for training and predicts 6 data points. After prediction,
model again learns with next 576 data points. Each data point represents 5 minutes
state. The iterative process of updating weights is done because the impact of input
features on blood glucose varies with time ( Bergman et al. (1981); Lee et al. (1992);
Van Cauter et al. (1992)). This model is also patient specific model as the effect of
every features on glucose differs inter- individually.
The next chapter discusses about the physiological model used as a guide to our
proposed SVR model for estimation of blood glucose.
16
Chapter 5
GLUCOSE REGULATION MODELING APPROACH
Glucose and insulin dynamics have been modeled since early 20th century, thus,
many models have been proposed for the estimation of blood glucose. These mathe-
matical models are used to estimate the glucose disappearance and insulin sensitivity,
a part of glucose-insulin dynamics research. These models can be classified mathemat-
ically as: ordinary differential equations Steil et al. (2005); Bolie (1961); Bergman
et al. (1981); Parker et al. (1999), delay differential equations Engelborghs et al.
(2001); Bennett and Gourley (2004), partial differential equations Wach et al. (1995);
Keener (2001), stochastic differential equations Bleckert et al. (1998); De Vries and
Sherman (2000), and integro-differential equations De Gaetano and Arino (2000); Li
et al. (2006).
Figure 5.1: Two Compartment Based Bergman Minimal Model
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In this work, modified Bergman Minimal Model ( Bergman et al. (1981)) is used for
estimation of BG levels. The BMM model was proposed in early eights by Bergman
et al. (1981) for the interpretation of glucose and insulin dynamics. This thesis also
modifies BMM for more accurate estimation of BG levels by inducing the effect of
physical activity intensity and endogenous glucose production on the blood glucose.
This model consists of two physiological compartment model: a glucose compartment,
and a plasma insulin compartment which effects the glucose remotely. For profound
understanding of the minimal model, I attempt to explain the two compartment
based model in simpler manner, dividing it into two parts: a glucose subsystem and
an insulin subsystem.
5.1 Glucose Subsystem
Figure 5.2: Minimal model for glucose kinetics. Source: Van Riel (2004)
The glucose subsystem consists of a set of three differential equations- glucose
plasma concentration, interstitial insulin and insulin plasma. Figure 5.2 summarizes
the minimal model for glucose kinetics.
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As depicted from 4.1 equation, glucose leaves or enters the plasma compartment
at a rate proportional to the difference between the plasma glucose level, G(t) and
the basal plasma level, Gb; if the plasma glucose level falls below the basal level,
glucose enters the plasma compartment, and if the glucose level rises above the basal
level, glucose leaves the plasma compartment. Glucose also disappears from the
plasma compartment via a second pathway at a rate proportional to the ””activity”
of insulin in the interstitial tissue X(t). ( Van Riel (2004))
Similarly, in equation 4.3, Insulin leaves or enters the interstitial tissue compart-
ment at a rate proportional to the difference between the plasma insulin level, I(t),
and the basal plasma level, Ib; if the plasma insulin level falls below the basal level,
insulin leaves the interstitial tissue compartment, and if the plasma insulin level
rises above the basal level, insulin enters the interstitial tissue compartment. Insulin
also disappears from the interstitial tissue compartment via a second pathway at
a rate proportional to the amount of insulin in the interstitial tissue compartment.
( Van Riel (2004))
In this work, equation 4.1 is modified by adding two more elements to the base
BMM, physical activity factor PA (coorelation of physical activity and BG levels is
explained later in this chapter) and endogenous glucose production (EGP) - EGP0(1+
X(t)). As explained by Hovorka et al. (2004), the minimal model insulin sensitivity is
tightly and linearly related to sensitivity of EGP, thus to quantify effects of interstitial
insulin on endogenous production of glucose, EGP is accumulate with X(t).
The glucose kinetics equations are described as below :
dG
dt
= −(p1 + PA)(G(t) − Gb) − X(t)G(t) + m(t) + EGP0(1−X(t))
Vg
(5.1)
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dX
dt
= −p2X(t) + p3I(t) (5.2)
dI
dt
=

γ(G(t)− h) ∗ t− n(I(t) + Ib) + U(t)VI , if G(t) ≥ h
−n(I(t) + Ib) + U(t)VI , otherwise
(5.3)
where,
G(t)(mg/dl) is the relative differential plasma glucose,
Gb(mg/dl) is the basal glucose,
X(unitless) represents the remote effects of insulin on glucose distribution and en-
dogenous glucose production.
I(t)(µI/dl) is the blood insulin concentration
Ib(µI/dl) is the basal insulin concentration
P1(min
−1) is the glucose ”mass action” rate constant
P2(min
−1) is the rate constant expressing the spontaneous decrease of tissue glucose
uptake ability
P3(min
−1) is the insulin-dependent increase in tissue glucose uptake ability, per unit
of insulin concentration excess over baseline insulin
n(min−1) is the first order decay rate constant for Insulin in plasma
γ(min−1) is the rate of pancreatic release of insulin after the bolus, per minute and
per mg/dl of glucose concentration above the target glycemia
h(mg/dl) is the pancreatic ”target glycemia”
VI(dl/kg) is the glucose volume distribution
VG(dl/kg) is the insulin volume distribution
m(t)(mg) is the effect of carbohydrate intake on plasma glucose
EGP0(mg/dl) represents endogenous glucose production extrapolated to the zero in-
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sulin concentration
U(t)(µI/dl) is the modification for T1DM in which insulin appears only from an
exogenous source
Figure 5.3: Meal Intake Sub-Model
Gillis et al. (2007) added one more component, meal intake sub-model, to stim-
ulate the dynamics of insulin, more accurately. The meal sub-model which describes
meal dynamics with input of carbohydrate (mg) is based on the gut absorption model
proposed by Hovorka et al. (2004).
According to the Gillis et al. (2007), meal sub-model is expressed as a two com-
partment gut absorption model:
dm
dt
=
−1
tmaxG
m(t) +
1
tmaxG
g(t) (5.4)
dg
dt
=
−1
tmaxG
g(t) +
Ag
tmaxG
Dg(t) (5.5)
where,
g(t)(mg) is the glucose appearance in the first compartment,
m(t)(mg) is the plasma appearance of glucose, input to the Bergman minimal model.
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5.2 Insulin Subsystem
Figure 5.4: Insulin Sub-Model
According to the Hovorka et al. (2004) model, the insulin absorption model
is also a two compartment based model which describes the subcutaneous insulin
transportation to plasma insulin and its effect on glucose production. The model is
described as below:
dS2
dt
=
−S1(t)
tmaxI
− S2(t)
tmaxI
(5.6)
dS1
dt
= −u(t)− S1(t)
tmaxI
(5.7)
where,
S1,S2 is the amount of insulin in first and second compartment,
tmaxI is the time -to-maximum insulin absorption,
u(t) is the administration of insulin, which is basal and bolus infusion.
The plasma appearance rate is given as:
U(t) =
S2
tmaxI
(5.8)
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5.3 Model Parameter
In this model, out of thirteen parameters, six parameters were estimated using
a nonlinear least square curve fitting algorithm and rest were kept constant. The
reason of doing so was to reduce the estimated parameters while keeping the capacity
to cover wide range of glucose variation observed in T1DM subjects. According to
the Hovorka et al. (2004), Table 5.1 represents the constant parameters along-with
the values used for T1DM subjects.
Table 5.1: Constant Parameters of Model
Symbol Description Value
EGP0 Endogenous Glucose Production 0.0161 µkg
−1min−1
Vg Glucose Distribution Volume 0.16 LKg
−1
VI Insulin Distribution Volume 0.12 LKg
−1
tmaxG Time-to-maximum of CHO absorption 40 min
−1
tmaxI Time-to-maximum of injected insulin 55 min
−1
Ag Carbohydrate Bio-availablity 0.8 unitless
Table 5.2 represents the estimated parameters by minimizing a weighted non-linear
least square function recursively. A non-linear square function is a regression analysis
approach estimates the unknowns in given equations. In this approach the overall
solution minimizes the sum of the squares of the difference between the observed
values and fitting value from the model. Least square problems fall into two categories:
linear and non-linear squares depending whether fitting equation are linear and non-
linear. Estimated parameters were constrained with upper and lower bound to keep
physiological features of the models.
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Table 5.2: Estimated Parameters of Model
Symbol Description Upper bound Lower bound
P1 Glucose Transfer Rate(min
−1) 7 ∗ 10−3 4.6 ∗ 10−2
P2 Deactivitation Rate(min
−1) 3.4 ∗ 10−3 6.7 ∗ 10−2
P3 Activitation Rate(min
−1) 5.5 ∗ 10−7 1.9 ∗ 10−5
n Fraction Elmination Rate(min−1) 0.1 0.5
Gb Basal Glucose Value(mg/dl) 40 200
Ib Basal Insulin Value(µI/dt) 0 365
5.4 Correlation between Physical Activity and Blood Glucose
According to Derouich and Boutayeb (2002); Control et al. (1995); UKPDS
(1998); Boutayeb and Kerfati (1994), long-term complications such as heart disease,
cancer, lipid levels can be avoided or at least delayed by a good regular control of
glycemia. A good regular control of glycemia needs proper dose of insulin for con-
trolling BG levels. According to the authors of the recent papers Bellazzi et al.
(2001); Derouich and Boutayeb (2002), the regulation of blood glucose concentration
is mainly achieved by acting on three control variables: insulin, meals and physical
exercise. However, all the proposed control systems have focused on the definition
of insulin therapy strategies and considering meals and physical exercise as (known)
disturbances. Further, though a lot of medical literatures have been published on
the effect of physical activities on BG levels and how physical activity is a contribut-
ing factor in hypoglycemia events, most of them do not go on to build an accurate
mathematical model which takes physical activity’s effects into account.
According to the Colberg et al. (2015), the impact of physical activity(PA) on BG
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levels is quite complicated since there are many dependent parameters such as type,
duration and intensity of physical activity which influences the effect on BG levels.
To measure the intensity of physical activity, numerically, we have used figures from
a wearable device called accelerometer sensors. These accelerometer sensors capture
the body movement for every five minute in all the three orientations.
Figure 5.5: Intensity of Physical Activity versus Decrease in BG levels.
Figure 5.5 represents the variation of BG levels against the intensity of physical
activity for every 30 minutes over a week long period. The intensity of physical
activity is numerically defined as area under curve of accelerometer readings and
decrease in BG is the difference between maximum and minimum BG levels in that
particular 30 minutes. The figure 5.5 clearly demonstrates a linear dependency of
PA on BG levels but this linearity is piecewise. This piecewise linearity means the
influence of PA on BG levels differs non−linearly on complete range but looking in
slots, the impact is linear. As mentioned by Colberg et al. (2015), the impact of
physical activity on blood glucose changes with respect to the intensity of physical
activity. Through our analysis we can clearly conclude that intensity of physical
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activity can be categorized in three - low, medium, and high. The effect of low
intensified activity on BG levels will be less as compared to the high one. This
effect is accounted in estimation of blood glucose levels by adding physical activity
factor(PA). PA component is described as below:
PA =
k1 ×DG
(Gmean × IPA) (5.9)
where k1 is the slope factor which is dependent on intensity of physical activity.
DG is difference between max and mini BG levels and Gmean is the mean of BG
levels. IPA is the intensity of physical activity for the particular time period which
is 5 minutes.
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Chapter 6
EXPERIMENTS AND RESULTS
6.1 Subjects and Protocols
For this research, data was gathered by Mayo clinic. Mayo Clinic captured contin-
uous variation of variables- food intake, physical activity and limitations of current
insulin preparations and use, influencing blood glucose. Blood glucose levels were
monitored every 5 minutes by DexCom G4 Platinum Profession CGM and physi-
cal activity was measured every 5 minutes by highly accurate accelerometers, wore
around the waist, that capture data on body movements. Mayo Clinic followed a
meal plan provided by the CRU metabolic kitchen during the one week CGM and
physical activity monitoring protocol. This weighed meals include 55% carbohydrate,
15% protein and 30% fat. Mayo Clinic provided us a dataset of 6T1DM subjects who
underwent the above protocols for 1 -week in free living scenario.
6.2 Power Analysis for Estimation of Sample Size
Coming up with an optimum sample size is a crucial factor in experimental design
as too many participants in an experiment can be very expensive whereas less number
of participants can result in an underpowered study resulting into inaccurate results
( Suresh and Chandrashekara (2012)). Power analysis is one such procedure which
allows us to determine the sample size required to detect the effect of given sample
size on the experiments such that we get statistically significant results. Power Anal-
ysis depends on four interrelated variables viz. Power, Significance level, Alternate
Hypothesis and Sample Size. If any three of them are known, it is possible to esti-
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mate the fourth one. We use this concept to derive the sample size. The alternative
hypothesis that we have used here is that the two means will differ (Two sided) .
Significance level corresponds to the probability of false positives. Sample size is the
number of subjects that we aim to estimate in Power Analysis. We set up a null
hypothesis stating there is no difference between the means and disproves it. It can
result in 2 errors. First error, Type II error can occur if we find a true difference then
the null hypothesis is rejected and we get a false negative result. Type I error can
occur as false positive is detected when it is found that there is a difference but in fact
is just due to the chance sample variation. The results of power analysis done in this
study are shown in the figure 6.1 in the form of power vs. number of observations.
450 observations were recorded for 7 subjects. The power for sample size 350 was
observed to be 0.08 and for 400, it was 1.00. In conclusion, an effective sample size
should be at least greater than 350.
Figure 6.1: Power Analysis graph to estimate effective size
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6.3 Preprocessing And Experiment Execution
This work generates a subject specific model for estimation of BG levels. we
followed a strategy generally used in a game called chess. In this strategy, on the basis
of past game, next few ahead moves are decided but only first move is implementation,
and then again our decided steps are re-assessed with opponent’s move. Similarly we
provide two days data and next 30 minutes values, after this prediction again we
learns the with two days and estimate 30 minutes data. The reason of doing so is to
include the daily changes done in the person’s activity. Another thing, physiological
parameter estimation using least square optimization is done only one time unlike
Bergman Minimal Model. In BMM, the parameters are estimated time-to-time for
inclusion of changes in the effectiveness of physiology variable.
With this strategy, the preprocessing time required is the time required to estimate
physiology parameters for every subject. Runtime execution is the time required for
the prediction of BG levels for next 2 days in a iteratively manner. This means after
every six prediction we update the weights of SVR by providing next 2 days data.
Table below shows the preprocessing time(time required fr estimation of physiological
parameters through optimization), execution time for 6 prediction (Time required for
prediction of 6 values without any weight updated of SVR model) and execution time
for 300 predictions (Time required for prediction with relearn of SVR after every 6
predictions)
6.4 Evaluation and Outcome
The data collected from seven Type I Diabetes patients over a period of three
days was subjected to the model mentioned above. Experiments were carried out to
evaluate the estimation of BG levels by BMM and SVR while factoring in the effects
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Table 6.1: Execution time required by Guided SVR model
Subjects Preprocessing time (sec) Execution Time for 6 prediction(sec) Execution time for 300 predictions(sec)
1 527 0.003 55
2 397 0.010 43
3 437 0.017 45
4 689 0.002 78
5 378 0.0087 35
6 435 0.019 59
7 397 0.007 49
of physical activity and EGP. The evaluation metric of these experiments was the
Root Mean Squared Error (RMSE). This metric is used to measure the deviation of
the predicted values of blood glucose levels from the actual blood glucose values or
the ground truth values. The lower RMSE values denotes that the predicted values
are being estimated with more accuracy. Since the inputs were standardized to zero
mean and unity standard deviation, preferred RMSE values lie as close to zero as
possible for high accuracy predictions.
Table 6.2 shows RMSE values of glucose levels, estimated by three different BMM
models - BMM without PA and EGP (Model I), BMM with PA (Model II) and BMM
with PA and EGP (Model III) - for seven subjects. We observe that Model III which
includes both physical activities and EGP effects outperforms other two models. One
more thing which is observed, is the difference of RMSE values between model II and
model III is quite less and this is because EGP effects comes into play when BG levels
goes below certain level thus it is averaged out.
Table 6.3 shows RMSE values of glucose levels, predicted by four different SVR
models - SVR without bergman estimation as a guide path (Guided Model I), SVR
without PA and EGP(Guided Model II), SVR with PA effects (Guided Model III)
and SVR with PA and EGP(Guide Model IV). Comparing RMSE values from table
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Table 6.2: RMSE Values for Bergman Minimal Model
Subjects Model I Model II Model III
1 0.555 0.408 0.410
2 0.523 0.404 0.394
3 0.551 0.501 0.537
4 0.566 0.466 0.473
5 0.653 0.503 0.455
6 0.577 0.474 0.420
7 0.639 0.554 0.492
6.2 and table 6.3 clearly concludes that SVR models outperform BMM models in
free living scenario.
Through this values we observe that the RMSE values are very high in the case
of SVR model without guide by the estimated values of glucose. This indicates that
the support vector regression models were unable to learn the underlying pattern and
hence unable to predict the correct values of blood glucose for the given into values.
Without any notion of the pharmacokinetics involved in the data, the support vector
regression models are unable to learn the trends the input data.
Another interesting thing which we can draw out from the results is that the
performance guided models becomes better by 10 % when physical activity and en-
dogenous glucose production effects are introduced. But there are few subjects for
which SVR model with only physical activity outperformed. The reason behind this
is that the correlation of EGP effect with actual glucose is quite low, as EGP comes
into play only when glucose levels goes down to a certain level.
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Table 6.3: SVR Models
Subjects Model I Model II Model III Model IV
1 0.428 0.241 0.164 0.169
2 0.221 0.054 0.043 0.044
3 0.335 0.157 0.128 0.154
4 0.417 0.275 0.256 0.249
5 0.369 0.174 0.162 0.167
6 0.376 0.219 0.204 0.194
7 0.451 0.231 0.16 0.091
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Chapter 7
CONCLUSION AND FUTURE WORK
This work proposed a guided machine learning framework for pharmacokinetic mod-
eling. This framework’s practicality is evaluated by implementing a support vector
regression model for blood glucose regulation. This model is build on to a physi-
ological model, which provides estimated blood glucose values. Our result analysis
concludes three things. First, a guided machine learning predicts physiological fea-
tures more accurately as compared to physiological based pharmacokinetic model.
This model is also less computational expensive. Second, through the results, we can
conclude that if all effecting factors are included in estimation by physiological, we
will obtain values more close to the actual values. Thirdly, these machine learning
models can be in a plug-n-play manner unlike physiological model and these guided
models can be used in the controlled system. Areas of future works can be classified
as follows:
• The proposed model’s practically is evaluated with one physiological model.
In the future work, the proposed model’s should be extend for every kind of
physiological model( Bagade et al. (2016), Bagade et al. (2013)).
• These regression models are being evaluated for seven subjects but when it
comes to health model it is quite important to evaluate test throughly in clinical
environment( Banerjee et al. (2012)).
• An end to end pervasive system which would monitor real time activities and
generate a subject specific regression estimation model. This system will provide
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more flexibility incorporating this system in free living environment ( Gupta
et al. (2013), Banerjee and Gupta (2015), Banerjee et al. (2013)).
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